Rx Felycin-CA1 (sirolimus delayed-release tablets) for Cats, 12 ct

Rx Felycin-CA1 (Sirolimus Delayed-Release Tablets), 12 Tablets

Felycin-CA1 (sirolimus delayed-release tablets) is the first FDA conditionally approved, once-weekly prescription medication designed to help manage ventricular hypertrophy in cats diagnosed with subclinical hypertrophic cardiomyopathy (HCM). This innovative therapy is formulated to help slow disease progression and support long-term heart health in affected cats.

HCM is a common and often silent condition affecting many cats. Felycin-CA1 offers a disease-modifying approach, giving veterinarians and pet owners a proactive option to help manage this condition before clinical signs appear.

Features:

• First FDA conditionally approved treatment for subclinical HCM in cats
• Disease-modifying therapy designed to help manage ventricular hypertrophy
• Convenient once-weekly oral dosing
• Small, easy-to-administer delayed-release tablets
• Helps support long-term cardiac health in affected cats
• Prescription-only medication for use under veterinary supervision

Active Ingredient:

Sirolimus

Directions:

Administer orally as directed by your veterinarian. May be given with or without food. Follow your veterinarian’s instructions closely for dosing and monitoring.

Important Safety Information:

Do not use in cats with diabetes mellitus or pre-existing liver disease. Discontinue immediately if diabetes develops during treatment. Use caution when administering with medications that affect cytochrome P-450 3A4 or P-glycoprotein, as this may increase the risk of toxicity. Regular bloodwork monitoring is recommended during treatment.

The most commonly reported adverse effects include cardiovascular-related events associated with progression of HCM, as well as lethargy, vomiting, diarrhea, and decreased appetite. This product has not been evaluated in cats with certain medical conditions, including kidney disease, hyperthyroidism, or other systemic illnesses.

For use only in otherwise healthy cats diagnosed with subclinical HCM and without a history of congestive heart failure or other significant cardiac complications. Not for use in breeding animals.

Not for human use. Keep out of reach of children and other animals. Pregnant or breastfeeding individuals should avoid contact. In case of accidental ingestion, contact a physician immediately.

Note:

Felycin-CA1 is conditionally approved by the FDA, meaning it has demonstrated safety and a reasonable expectation of effectiveness while additional studies are ongoing.

 

This product requires a Valid prescription.

All prescription items are Non-Refundable and Non-Returnable.